Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tarlatamab-dlle

View Patient Information
A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) fused to one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, tarlatamab binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and the DLL3 antigen found on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-DLL3 x anti-CD3 BiTE AMG 757
bispecific T-cell engager antibody AMG 757
BiTE antibody AMG 757
DLL3/CD3-directed bispecific T-cell engager antibody AMG 757
tarlatamab
US brand name:Imdelltra
Code name:AMG 757
AMG-757
AMG757
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search